News

Meningococcal B vaccine less protective than expected during outbreak

View on the News

MenB vaccine presents challenges in making public health recommendations

Proving the clinical efficacy of Neisseria meningitidis serogroup B (MenB) vaccines has been difficult. There is substantial genetic (and corresponding antigenic) diversity, and serogroup B meningococcal disease is both uncommon and in decline in countries where the burden is well understood. The Advisory Committee on Immunization Practices reviewed available data and concluded that a public health recommendation for vaccination of all adolescents could not be supported but that sufficient evidence existed to support individual decision making by clinicians with regard to patients between 16 and 23 years of age. Vaccination of all adolescents would prevent 15-29 cases and five to nine deaths annually in the United States. The effect of vaccinating college students is correspondingly smaller – preventing perhaps nine cases and one death, at an estimated cost per quality-adjusted life-year of $9.4 million.

The Centers for Disease Control and Prevention notes that the MenB vaccines approved in the United States should provide “protection against most, but not all, serogroup B strains” and represent an important contribution to the prevention of serogroup B meningococcal disease. More than 60,000 persons have received at least one vaccination with 4CMenB in studies conducted worldwide, including studies at universities in the United States and Canada, and the safety profile for 4CMenB has been good. For a relatively uncommon but devastating infectious disease, the regulatory approval of a vaccine in the absence of ideal data may be necessary and appropriate if the vaccine is deployed in the context of a systematic public health response and if there is a commitment to the generation of additional information necessary for determining recommendations for use. The regulatory approval and clinical use of vaccines for pathogens that cause outbreaks will remain challenging.

Jerome H. Kim, MD, is with the International Vaccine Institute in Seoul, South Korea. He reported having no relevant financial disclosures. These comments were excerpted from the editorial accompanying the study (doi:10.1056/NEJMe1606015).


 

FROM THE NEW ENGLAND JOURNAL OF MEDICINE

References

One-third of the individuals who received a multicomponent meningococcal B vaccine during an outbreak did not show a protective response against the outbreak strain, though they also did not contract the disease, a study showed.

“This level of seropositivity was lower than expected, given the antigenic similarity between the outbreak strain and the components of the vaccine and given that the Meningococcal Antigen Typing System predicted that 4CMenB would induce responses against the outbreak strain,” Nicole E. Basta, PhD, of the University of Minnesota, Minneapolis, and her associates wrote in the New England Journal of Medicine (2016;375:220-8. doi:10.1056/NEJMoa1514866).

©Steve Mann/thinkstockphotos.com

“Our results indicate that knowledge of [human complement serum bactericidal antibodies] immunity against the vaccine reference strains is not sufficient to predict individual-level immunity against an outbreak strain, even when the strain expresses one or more antigens that are closely related to the vaccine antigens,” the investigators added.

Amidst an outbreak of meningococcal B at Princeton (N.J.) University in the winter of 2013, the Food and Drug Administration allowed use of the meningococcal serogroup B (4CMenB) vaccine before its licensure, in an attempt to control the outbreak. Two strains of meningitis were used in developing this vaccine: 5/99 strain, which was not at all similar to the outbreak strain, and 44/76-SL, which was 96% genetically similar to the outbreak strain.

Among 535 people who completed the study, 499 individuals received two doses of 4CMenB 10 weeks apart, 17 received one dose of the vaccine, and 19 were unvaccinated. When the fully vaccinated individuals were tested for titers 8 weeks after their second dose, two-thirds (66.1%) had low-level seropositivity for the outbreak strain, with a geometric mean titer (GMT) of 7.6. One in five of the unvaccinated people (21.1%) had low seropositivity for the outbreak strain (GMT, 2.8), and 58.8% of the partly vaccinated individuals had seropositivity with a GMT of 5.4.

The researchers then assessed titers for the two strains used in developing 4CMenB in 61 fully vaccinated individuals, all randomly selected from the one-third of fully vaccinated people who did not have a detectable response to the outbreak strain. Most of them (86.9%) were seropositive for the 44/76-SL strain with a GMT of 17.4, and all of them were seropositive for the 5/99 strain, with a considerably larger GMT of 256.3.

Among those fully vaccinated who responded to the outbreak strain with titers above 8, all had seropositivity for 44/76-SL (GMT, 178.8), and 96.7% had seropositivity for the 5/99 strain (GMT, 214.2). Among the 18 unvaccinated individuals, just 1 had very low seropositivity to the 5/99 strain (GMT, 1.2), and 6 of them (33.3%) responded to the 44/76-SL strain (GMT, 3.2).

“These findings have implications for vaccination policies aimed at preventing and controlling meningococcal B disease,” the authors wrote.

The research was funded by Princeton University, the National Institutes of Health, and the Department of Homeland Security. Dr. Bai, Dr. Borrow, and Dr. Findlow reported having previously received research funding, unrelated to this study, from GlaxoSmithKline, Novartis, Pfizer, and Sanofi Pasteur. Dr. Johnsen has been reimbursed for travel expenses from Pfizer for a presentation. No other authors had financial disclosures.

Recommended Reading

ACIP votes to scrap LAIV vaccine for 2016-2017 influenza season
MDedge Family Medicine
ACIP hints at move from three-dose to two-dose HPV vaccination schedule for youth
MDedge Family Medicine
Zika vaccine development to get underway
MDedge Family Medicine
Novel vaccine scores better hepatitis B seroprotection in type 2 diabetes
MDedge Family Medicine
Appreciate family cognitive style when discussing vaccines
MDedge Family Medicine
Malaria vaccine disappoints in phase II trial
MDedge Family Medicine
Incidence of HPV-associated cancers on the rise
MDedge Family Medicine
9-valent, quadrivalent HPV vaccines have comparable safety
MDedge Family Medicine
HPV vaccination rates not improved by increased awareness
MDedge Family Medicine
DTaP/IPV plus bivalent rLP2086 vaccine deemed noninferior in adolescents
MDedge Family Medicine